https://www.selleckchem.com/pr....oducts/pf-05221304.h
These strategies used here can be considered for developing microbial cell factory of other L-aspartate derivatives. Addition of immune checkpoint inhibitors to neoadjuvant chemotherapy (NACT) is a promising strategy in early breast cancer, but the optimal duration of therapy is currently unknown. In the GeparNuevo (NCT02685059) trial, addition of durvalumab to NACT as previously reported led to a moderate increase in pathological complete response (pCR) rate by an absolute 9% (P= 0.287). Patients with cT1b-cT4a-d triple-negative br
Like
Comment
Share
